Related Experiment Video
Updated: Mar 26, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in
Christoph B Olivier1, Katharina Schnabel2, Susanne Weber3
1Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Insights
Body weight affects antiplatelet therapy response in myocardial infarction patients. Unlike clopidogrel, third-generation P2Y12 inhibitors like prasugrel and ticagrelor show consistent platelet inhibition regardless of patient weight.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Standard antiplatelet therapy for myocardial infarction (MI) involves P2Y12 receptor antagonists: clopidogrel, prasugrel, and ticagrelor.
- Platelet reactivity to clopidogrel is known to be influenced by factors like body weight.
- The impact of such factors on prasugrel and ticagrelor efficacy remains less understood.
Purpose of the Study:
- To investigate factors associated with high residual platelet reactivity.
- To compare residual platelet reactivity after administration of third-generation P2Y12 antagonists (prasugrel, ticagrelor) versus clopidogrel.
- To determine if body weight influences the antiplatelet effect of these agents in MI patients.
Main Methods:
- A single-center registry study analyzed the antiplatelet effects of clopidogrel, prasugrel, and ticagrelor in 238 MI patients.
- Platelet aggregation was assessed using aggregometry, stimulated with thrombin receptor activating peptide (TRAP) and adenosine diphosphate (ADP).
- Relative ADP-induced aggregation (r-ADP-agg), calculated as the ADP-TRAP ratio, quantified P2Y12-dependent platelet inhibition.
Main Results:
- Residual platelet reactivity (r-ADP-agg) significantly correlated with body weight in patients receiving clopidogrel (r=0.423, p<0.001).
- This correlation was not observed in patients treated with prasugrel (r=-0.117, p=0.354) or ticagrelor (r=-0.082, p=0.382).
- A significant difference in correlation coefficients (p=0.003) confirmed that body weight impacts clopidogrel response but not prasugrel or ticagrelor.
Conclusions:
- Unlike clopidogrel, the antiplatelet activity of prasugrel and ticagrelor is independent of body weight in myocardial infarction patients.
- These findings support clinical trial data suggesting that dose adjustments for third-generation P2Y12 antagonists are unnecessary for high-body-weight individuals.
- Consistent platelet inhibition with prasugrel and ticagrelor simplifies antiplatelet therapy selection in diverse patient populations.
Abstract:
The current standard of antiplatelet therapy for patients with myocardial infarction (MI) includes the P2Y12-receptor antagonist clopidogrel, prasugrel or ticagrelor. While it has been shown that platelet reactivity after clopidogrel administration depends on factors such as body weight, it is not known if these factors have an effect on the activity of prasugrel or ticagrelor. Thus, this study aimed to analyse factors associated with high residual platelet reactivity after administration of third generation P2Y12-antagonists compared to clopidogrel. In a single centre registry the antiplatelet effect of clopidogrel, prasugrel or ticagrelor was investigated by aggregometry in patients after MI. To assess the overall capacity of platelet aggregation whole blood was induced with thrombin receptor activating peptide (TRAP; 32 µM). To specifically quantify the effect of P2Y12-antagonists, blood was stimulated with 6.4 µM adenosine diphophosphate (ADP). Relative ADP induced aggregation (r-ADP-agg) was defined as the ADP-TRAP-ratio to reflect an individual degree of P2Y12-dependent platelet inhibition. Platelet function of 238 patients was analysed [clopidogrel (n = 58), prasugrel (n = 65), ticagrelor (n = 115)]. It was found that the r-ADP-agg correlated significantly with body weight in patients after clopidogrel administration (r = 0.423; p < 0.001). In contrast, this association was not present in patients after prasugrel (r = -0.117; p = 0.354) or ticagrelor (r = -0.082; p = 0.382) administration. Comparison of the correlation coefficients showed a significant difference (p = 0.003). In contrast to clopidogrel, platelet reactivity after administration of prasugrel or ticagrelor does not depend on body weight in patients after MI. Hence, our mechanistic data support the results of large clinical trials indicating that patients with high body weight do not need to be treated with increased doses of third generation P2Y12-antagonists to achieve sufficient platelet inhibition (registry for patients after myocardial infarction treated with antiplatelet agents; DRKS00003146).
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...